troxacitabine has been researched along with cytosine in 67 studies
| Studies (troxacitabine) | Trials (troxacitabine) | Recent Studies (post-2010) (troxacitabine) | Studies (cytosine) | Trials (cytosine) | Recent Studies (post-2010) (cytosine) |
|---|---|---|---|---|---|
| 72 | 17 | 2 | 11,168 | 142 | 3,214 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (11.94) | 18.2507 |
| 2000's | 57 (85.07) | 29.6817 |
| 2010's | 2 (2.99) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, SK; Alves, AJ; Beach, JW; Choi, BG; Chu, CK; Jeong, LS; Kim, HO; Schinazi, RF; Van Roey, P | 1 |
| Cheng, YC; Chu, CK; Gao, Z; Grove, KL; Guo, X; Liu, SH | 1 |
| Cheng, YC; Grove, KL | 1 |
| Boudinot, FD; Chu, CK; Moore, LE | 1 |
| Angers, EG; Attardo, G; Bednarski, K; Bibeau, L; Bowlin, TL; Cimpoia, A; DeMuys, JM; Kadhim, SA; Waud, WR | 1 |
| Attardo, G; Bowlin, T; Harakidas, P; Rabbani, SA | 1 |
| Attardo, G; Cerna, C; Davidson, K; Finkle, C; Gomez, L; Izbicka, E; Lawrence, R; Marsolais, C; Rowinsky, EK; Siu, LL; Von Hoff, DD | 1 |
| Cheng, YC; Haggerty, JG; Schwartz, PM | 1 |
| Jolivet, J; Locas, C; Marty, J; Von Hoff, DD; Weitman, S | 1 |
| Cheng, YC; Chou, KM; Kukhanova, M | 1 |
| Baker, SD; Beran, M; Bivins, C; Cortes, JE; Giles, FJ; Jolivet, J; Kantarjian, HM; O'Brien, S; Smith, TL; Thomas, DA | 1 |
| Bernier, L; Bibeau, L; Bowlin, T; Custeau, D; Gourdeau, H; Ouellet, F | 1 |
| Larson, RA | 1 |
| Dumontet, C; Galmarini, CM; Mackey, JR | 1 |
| Günzburg, WH; Salmons, B | 1 |
| Johnson, SA | 1 |
| Cass, CE; Clarke, ML; Gourdeau, H; Jolivet, J; Lafrenière, RG; Lee, N; Mackey, JR; Mowles, D; Ouellet, F; Richard, A; Selner, M; Young, JD | 1 |
| Baker, SD; de Bono, JS; Goetz, A; Hammond, LA; Hidalgo, M; Jolivet, J; Patnaik, A; Rowinsky, EK; Simmons, C; Siu, L; Stephenson, J; Weiss, G | 1 |
| Giles, FJ | 3 |
| Andreeff, M; Baker, SD; Bivins, C; Cortes, JE; Garcia-Manero, G; Giles, FJ; Jolivet, J; Kantarjian, HM; Miller, CB; O'Brien, SM; Thomas, DA | 1 |
| Cortes, JE; Giles, FJ; Hui, YF | 1 |
| Baker, SD; Bélanger, K; Dionne, J; Jolivet, J; Maclean, M; Moore, M; Seymour, L; Siu, L; Soulières, D; Wainman, N | 1 |
| Karrison, T; Ratain, M | 1 |
| Cheson, BD | 1 |
| Alvarado, Y; Apostolidou, E; Bivins, C; Cortes, JE; Giles, FJ; Kantarjian, HM | 1 |
| Estey, E; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S | 1 |
| Ecker, G | 1 |
| Attardo, G; Bibeau, L; Bouffard, DY; deMuys, JM; Duchamp, O; Genne, P; Gourdeau, H; Kadhim, S; Ouellet, F | 1 |
| Baker, SD; Donehower, RC; Grochow, LB; Rowinsky, EK; Schellens, JH; Sparreboom, A; Verweij, J | 1 |
| Cheng, YC; Chou, KM | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Belanger, K; Bjarnason, GA; Chi, K; Ernst, DS; Goel, R; Jolivet, J; McIntosh, L; Moore, MJ; Ruether, JD; Seymour, L; Siu, LL; Stewart, D; Tannock, I; Townsley, CA | 1 |
| Berry, DA; Cortes, JE; Estey, EH; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Thomas, DA; Verstovsek, S; Wathen, JK; Xiao, LC | 1 |
| Albitar, M; Beran, M; Cortes, JE; Faderl, S; Feldman, EJ; Giles, FJ; Kantarjian, HM; Larson, RA; Mamus, SW; O'Brien, SM; Roboz, GJ; Talpaz, M; Verstovsek, S | 1 |
| Barbeau, S; Bouffard, DY; Gourdeau, H; Hamelin, B; Jolivet, J; Leblond, L; Ouellet, F; Richard, A | 1 |
| Cortes, J; Giles, F; Kantarjian, H; Ravandi, F | 1 |
| Beran, M; Cortes, J; Freireich, EJ; Giles, FJ; Golemovic, M; Gourdeau, H; Kantarjian, H; Orsolic, N; Verstovsek, S | 1 |
| Boivin, AJ; Gourdeau, H; Momparler, RL | 1 |
| Gourdeau, H; Jolivet, J | 1 |
| Cheng, YC; Dutschman, GE; Hsu, CH; Kim, TE; Park, SY | 1 |
| Boudreau, C; Custeau, D; Dong, K; Gilbert, MJ; Gourdeau, H; Hamelin, B; Jolivet, J; Leblond, L; Ouellet, F; Richard, A | 1 |
| Batist, G; Eatock, M; Hawkins, RE; Jolivet, J; Lapointe, R; Létourneau, R; Moore, M; Steward, W; Vincent, M; Whittom, R | 1 |
| Cheng, YC; Lam, W; Leung, CH; Park, SY | 1 |
| Baker, SD; Capparelli, E; Giles, F; Hidalgo, M; Jolivet, J; Lee, CK; Li, J; Moore, MJ; Rowinsky, EK | 1 |
| Adema, AD; Albertoni, F; Floor, K; Hubeek, I; Kaspers, GJ; Peters, GJ; Zuurbier, L | 1 |
| Allen-Bard, S; Curcio, TJ; Faderl, S; Feldman, EJ; Giles, FJ; Kantarjian, HM; Kelner, MJ; Park, SL; Ravandi, F; Ritchie, EK; Roboz, GJ; Wilkes, MA | 1 |
| Burley, SK; Hazra, S; Konrad, M; Lavie, A; Sabini, E | 1 |
| Baccarani, M; Belanger, R; Ben-Yehuda, D; Caballero, D; Coiffier, B; Facon, T; Fanin, R; Giles, F; Gregory, SA; Panwalkar, A; Vose, JM | 1 |
| Cortes, J; Quintás-Cardama, A | 1 |
| Adema, AD; Alexander, LE; Cho, JH; Chu, CK; Daft, JR; Hoebe, EK; Peters, GJ; Radi, M | 1 |
| Giles, F; Swords, R | 1 |
| Bussom, S; Cheng, YC; Lam, W; Leung, CH | 1 |
| Apostolidou, E; Giles, F; Swords, R | 1 |
| Bouffard, DY; Cass, CE; Clarke, ML; Damaraju, VL; Gourdeau, H; Grey, M; Leblond, L; Mackey, JR; Wong, CK | 1 |
| Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC | 1 |
| Adema, AD; Alexander, LE; Chu, CK; Daft, J; Hoebe, EK; Narayanasamy, J; Peters, GJ; Radi, M | 1 |
| Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Lee, CK; Ma, WW; Messersmith, WA | 1 |
| Faderl, S; Gandhi, V; Kantarjian, HM | 1 |
| Liu, X; Matsuda, A; Plunkett, W; Wang, Y | 1 |
| Bussom, S; Cheng, YC; Lam, W | 1 |
| Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW | 1 |
| Cortes, J; Giles, F | 1 |
| Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
16 review(s) available for troxacitabine and cytosine
| Article | Year |
|---|---|
New agents for induction and postremission therapy of acute myeloid leukemia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cytosine; Dioxolanes; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Topotecan | 2001 |
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Lymphoproliferative Disorders; Neoplastic Stem Cells; Nucleosides; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Remission Induction; Ribonucleotide Reductases; Vidarabine | 2001 |
Novel clinical strategies for the treatment of pancreatic carcinoma.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antineoplastic Agents; Bile; Biotransformation; Cancer Vaccines; Carcinoma; Clinical Trials as Topic; Cytochrome P-450 CYP2B1; Cytosine; Deoxycytidine; Dioxolanes; DNA, Antisense; Endopeptidases; Enzyme Inhibitors; Gemcitabine; Genes, p53; Genes, ras; Genetic Therapy; Heat-Shock Proteins; Humans; Ifosfamide; Multicenter Studies as Topic; Neoplasm Proteins; Neoplastic Stem Cells; Pancreatic Neoplasms; Pectins; Pilot Projects; Polyamines; Prospective Studies; Prostheses and Implants; Sesquiterpenes; Spiro Compounds; Tissue Extracts; Topoisomerase I Inhibitors | 2001 |
Nucleoside analogues in the treatment of haematological malignancies.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine | 2001 |
Novel agents for the therapy of acute leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Cysteine Endopeptidases; Cytosine; Decitabine; Dioxolanes; DNA Methylation; Humans; Leukemia; Multienzyme Complexes; Neovascularization, Pathologic; Proteasome Endopeptidase Complex | 2002 |
Troxacitabine-based therapy of refractory leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Cytosine; Dioxolanes; Humans; Idarubicin; Leukemia; Remission Induction; Topotecan | 2002 |
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
New agents in acute myeloid leukemia and other myeloid disorders.
Topics: Antineoplastic Agents; Cyclosporine; Cytosine; Deoxycytidine; Dioxolanes; Female; Gemcitabine; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Myeloid, Acute; Male; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2004 |
[Troxacitabine].
Topics: Acute Disease; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytosine; Dioxolanes; Drug Screening Assays, Antitumor; Humans; Leukemia; Neoplasms | 2004 |
Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Cytosine; Dioxolanes; Drug Evaluation, Preclinical; Humans; Leukemia, Myeloid, Acute; Nucleosides; Stereoisomerism | 2007 |
Troxacitabine in acute leukemia.
Topics: Antineoplastic Agents; Cytosine; Dioxolanes; Humans; Leukemia; Treatment Outcome | 2007 |
Troxacitabine in leukemia.
Topics: Antineoplastic Agents; Cytosine; Dioxolanes; Humans; Leukemia; Treatment Outcome | 2006 |
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cytosine; Dioxolanes; Humans; Leukemia, Myeloid, Acute; Nucleosides | 2008 |
New agents in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Cytosine; Dioxolanes; Farnesyltranstransferase; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Vaccination | 2003 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
16 trial(s) available for troxacitabine and cytosine
| Article | Year |
|---|---|
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Blast Crisis; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2001 |
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Eruptions; Female; Half-Life; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Regression Analysis; Salvage Therapy; Statistics, Nonparametric; Stereoisomerism; Structure-Activity Relationship | 2002 |
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 2002 |
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Dioxolanes; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Thrombocytopenia; Tissue Distribution | 2002 |
Troxacitabine activity in extramedullary myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytosine; Dioxolanes; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 2002 |
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cytosine; Dioxolanes; Female; Gemtuzumab; Hepatic Veno-Occlusive Disease; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Aged; Antineoplastic Agents; Canada; Carcinoma, Renal Cell; Cytosine; Dioxolanes; Disease Progression; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytosine; Dioxolanes; Female; Humans; Idarubicin; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival; Treatment Outcome | 2003 |
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytosine; Dioxolanes; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy | 2003 |
Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Body Weight; Cytosine; Dioxolanes; Disease Progression; Female; Health Status; Humans; Infusions, Intravenous; Male; Middle Aged; Pain; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Topics: Antineoplastic Agents; Body Fluid Compartments; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Middle Aged; Models, Biological; Molecular Structure; Neoplasms; Predictive Value of Tests; Structure-Activity Relationship | 2006 |
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Treatment Outcome | 2007 |
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged; Models, Biological; Multiple Myeloma; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Topics: Adult; Aged; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Predictive Value of Tests; Probability; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Tissue Distribution; Treatment Outcome; Young Adult | 2009 |
35 other study(ies) available for troxacitabine and cytosine
| Article | Year |
|---|---|
Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity.
Topics: Antiviral Agents; Cytosine; Dioxolanes; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Conformation; Molecular Structure; Pyrimidine Nucleosides; Structure-Activity Relationship | 1992 |
Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Colonic Neoplasms; Cytarabine; Cytosine; Dioxolanes; Drug Screening Assays, Antitumor; Humans; KB Cells; Leukemia P388; Liver Neoplasms; Male; Mice; Molecular Structure; Phosphorylation; Prostatic Neoplasms; Stereoisomerism; Tumor Cells, Cultured | 1995 |
Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line; Cytarabine; Cytosine; Dioxolanes; DNA, Neoplasm; Humans; Kinetics; Male; Prostatic Neoplasms; Tritium; Tumor Cells, Cultured | 1996 |
Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Cytosine; Dioxolanes; Male; Rats; Rats, Sprague-Dawley | 1997 |
Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cytosine; Dioxolanes; Drug Screening Assays, Antitumor; Female; Humans; Kidney Neoplasms; Mice; Neoplasm Transplantation; Nucleosides; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Division; Cytosine; Dioxolanes; Doxorubicin; Male; Prostatic Neoplasms; Rats | 1998 |
Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.
Topics: Antineoplastic Agents; Cytosine; Dioxolanes; Female; Humans; Kidney Neoplasms; Melanoma; Ovarian Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1998 |
Beta-L-1,3-dioxolane-cytidine: a novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro.
Topics: Antimetabolites, Antineoplastic; Cell Differentiation; Cell Division; Cell Size; Cells, Cultured; Cytosine; Dioxolanes; Humans; Keratinocytes; Protein Precursors; Zidovudine | 1998 |
The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Topics: Animals; Antineoplastic Agents; Body Weight; Cytosine; Deoxycytidine; Dioxolanes; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.
Topics: Anions; Antineoplastic Agents; Antiviral Agents; Blotting, Western; Carbon-Oxygen Lyases; Cations; Chromatography, Agarose; Chromatography, Ion Exchange; Cytarabine; Cytosine; Deoxycytidine; Deoxycytidine Monophosphate; Deoxyribonuclease IV (Phage T4-Induced); Dioxolanes; DNA; DNA-(Apurinic or Apyrimidinic Site) Lyase; Electrophoresis, Polyacrylamide Gel; Endonucleases; Humans; Oligonucleotides; Recombinant Proteins; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stereoisomerism; Thionucleosides; Tumor Cells, Cultured; Zalcitabine | 2000 |
Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
Topics: Animals; Antineoplastic Agents; Cell Division; Cytidine Deaminase; Cytosine; Dioxolanes; Female; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Leukemia, T-Cell; Mice; Mice, SCID; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Topics: Amino Acid Sequence; Antineoplastic Agents; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Male; Membrane Proteins; Molecular Sequence Data; Nucleoside Transport Proteins; Phosphorylation; Prostatic Neoplasms; Sequence Homology, Amino Acid; Sodium; Stereoisomerism; Tritium; Tumor Cells, Cultured; Uridine | 2001 |
Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Dioxolanes; Erythema; Female; Foot; Hand; Humans; Leukemia; Male; Middle Aged; Paresthesia; Recurrence; Syndrome | 2002 |
Troxacitabine in patients with refractory leukemia.
Topics: Antineoplastic Agents; Area Under Curve; Clinical Trials, Phase II as Topic; Cytosine; Dioxolanes; Humans; Leukemia; Treatment Outcome | 2002 |
Troxacitabine (Shire Pharmaceuticals).
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Humans; Neoplasms; Structure-Activity Relationship | 2002 |
Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Cell Division; Cytosine; Dioxolanes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Multidrug Resistance-Associated Proteins; Neoplasms, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Clinical Trials, Phase I as Topic; Cytosine; Dacarbazine; Dioxolanes; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Paclitaxel; Retrospective Studies; Temozolomide; Uracil | 2002 |
The exonuclease activity of human apurinic/apyrimidinic endonuclease (APE1). Biochemical properties and inhibition by the natural dinucleotide Gp4G.
Topics: Amino Acids; Carbon-Oxygen Lyases; CpG Islands; Cytosine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Dose-Response Relationship, Drug; Humans; Hydrogen-Ion Concentration; Kinetics; Magnesium Chloride; Mutagenesis, Site-Directed; Mutation; Nickel; Protein Conformation; Recombinant Proteins; Substrate Specificity | 2003 |
Troxacitabine: BCH 4556, SPD 758, Troxatyl.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Drug Industry; Humans; Infusions, Intravenous; Neoplasms; Treatment Outcome | 2003 |
Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Cell Line, Tumor; Cell Survival; Cytarabine; Cytosine; Dioxolanes; DNA, Neoplasm; Female; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Leukemia, Experimental; Mice; Mice, SCID; Neoplasm Transplantation | 2003 |
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Survival; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyrimidines; Survival Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
Action of troxacitabine on cells transduced with human cytidine deaminase cDNA.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytarabine; Cytidine Deaminase; Cytosine; Dioxolanes; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Transduction, Genetic; Tumor Cells, Cultured | 2004 |
Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Cytosine; Deoxycytidine Kinase; Dioxolanes; DNA Damage; Drug Screening Assays, Antitumor; Drug Synergism; Humans; KB Cells; Tumor Cells, Cultured | 2004 |
Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Male; Mice; Neoplasm Transplantation; Neoplasms; Species Specificity; Time Factors | 2004 |
Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcit
Topics: Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; RNA, Small Interfering; Transfection | 2006 |
Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells.
Topics: Antineoplastic Agents; Catalysis; Cell Line, Tumor; Cladribine; Cytosine; Deoxycytidine; Dioxolanes; Drug Resistance, Neoplasm; Gemcitabine; HeLa Cells; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Models, Chemical; Nucleosides | 2006 |
Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase.
Topics: Anti-HIV Agents; Antineoplastic Agents; Crystallography, X-Ray; Cytosine; Deoxycytidine Kinase; Dioxolanes; Humans; Lamivudine; Models, Molecular; Prodrugs; Stereoisomerism; Substrate Specificity | 2007 |
In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytosine; Dioxolanes; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Prodrugs; Stereoisomerism; Structure-Activity Relationship | 2007 |
The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Phosphoglycerate Kinase; Rhabdomyosarcoma | 2007 |
Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Deoxycytidine; Dioxolanes; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Treatment Outcome; Tritium; Tumor Cells, Cultured; Uridine; Xenograft Model Antitumor Assays | 2007 |
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan | 2007 |
Troxacitabine prodrugs for pancreatic cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytosine; Dioxolanes; Drug Design; Drug Screening Assays, Antitumor; Humans; Pancreatic Neoplasms; Prodrugs | 2007 |
Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Cytarabine; Cytosine; Dioxolanes; DNA Damage; DNA Repair; HeLa Cells; Humans; Mice; Transcription, Genetic; Tumor Suppressor Protein p53 | 2008 |
Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cytosine; Deoxycytidine; Dioxolanes; Dose-Response Relationship, Drug; Gemcitabine; Hemodynamics; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Proteins; Phosphoglycerate Kinase; Response Elements; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Female; Humans; Male; Middle Aged; Models, Biological; Monte Carlo Method; Neoplasms; Neutropenia; Young Adult | 2011 |